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Enhanced potassium ion permeability at the enterocyte basolateral membrane is assumed to facilitate sustained chloride ion and
ﬂuid secretion into the intestinal lumen during episodes of secretory diarrhoeal disease. To examine this concept in vivo,t w o
potassiumionchannelblockersandachannelopenerwerecoperfusedwithE.coliheatstableSTaenterotoxintodeterminewhether
such compounds improved or worsened the inhibited ﬂuid absorption. In the STa (80ng/mL) challenged jejunal loop, the ﬂuid
absorption rate of 28.6 ± 5.8 (14)µL/cm/hr was signiﬁcantly below (P<. 001) the normal rate of 98.8 ± 6.2 (17)µL/cm/hr.
Intraluminal (300uM) glibenclamide added to STa perfused loops failed to improve the inhibited ﬂuid absorption rate, which
was 7.4 ± 3.2( 6 )µL/cm/hr on coperfusion with STa. Similarly, on coperfusion with 30uM clotrimazole, the ﬂuid absorption rate
with STa present remained inhibited at 11.4±7.0( 4 )µL/cm/hr. On coperfusion with intraluminal 1uM cromakalim,STa reduced
ﬂuid absorption signiﬁcantly(P<. 02) to 24.7±8.0 (10)µL/cm/hr, no diﬀerent from STa challenge in the absence of cromakalim.
Infusion i.v. with these agents also failed to restore ﬂuid absorption after STa challenge. These observations do not support the
proposed potassium ion permeability event as a necessary corollary of enterotoxin-mediated secretion. This makes it unlikely that
modulators of such permeability prevent enterocyte secretion in diarrhoeal disease.
1.Introduction
Fluid and electrolyte absorption is an essential function of
theenterocytesofthesmall intestine.Inaddition,enterocytes
are assumed also to be capable of ﬂuid secretion into the
intestine resulting from the transport of chlorideion into the
lumen although this enterocyte origin of secretion has been
questioned [1, 2]. Net ﬂuid uptake is, therefore, regarded as
ﬂuid absorption opposed in part by an enterocyte secretory
process that can be enhanced by bacterial enterotoxins to
cause diarrhoeal disease. Chloride entry from the interstitial
ﬂuid into the enterocyte is achieved principally by the
NKCC cotransporter with subsequent transit through the
luminally sited CFTR channel. Given the adverse lumen
to the enterocyte interior chemical concentration gradient,
luminal exit of chloride ion can only arise through a
favourable electrical gradient across the luminal face of the
enterocyte.Maintenanceofthismembranepotentialthrough
modulation of basolateral potassium ion conductance is,
therefore,assumed tobeanimportant aspect ofthesecretory
process.
Many in vitro studies of electrical events in cell systems
after STa and cholera toxin challenge apparently conﬁrm
this aspect of the secretion model [3–5]. In contrast, there
have been only two previous in vivo studies on potassium
channel openers and blockers in the enterotoxin challenged
small intestine, and the most detailed account seems to
contradict the above model of the role of potassium ion
channel opening. Reduced ﬂuid absorption in vivo from the
rat jejunum after STa challenge was partially restored by
glibenclamide and also, less explicably, by cromakalim, the
potassium channel opener [6]. The other in vivo study, a2 Journal of Tropical Medicine
brief report onthe pigintestine, indicated thatthe potassium
channel blocker clotrimazole did not overcome the eﬀect of
STa challenge [7].
We report here on similar ﬁndings in the rat jejunum in
vivo on the eﬀect of clotrimazole, cromakalim, and gliben-
clamide on jejunal ﬂuid absorption in vivo in the rat
compromised by perfusion with E. coli STa enterotoxin.
These experiments intended to determine whether or not
K+-channel modulatorsadministered invivo couldrestore or
even further reduce the eﬀects of STa on ﬂuid absorption,
as has been hypothesised should occur on the basis of in
vitro ﬁndings. Jejunum was chosen rather than ileum, as the
jejunum has higher rates of ﬂuid absorption that are suscep-
tible to STa derangement. Ileum can be used, but absorption
rates are about one half those in the jejunum. When tested in
vivo, these potassium channel modulators had no eﬀect on
STa-inhibited ﬂuid absorption, making it unlikely that they
would be eﬀective antidiarrhoeal compounds. In addition,
the failure of potassium channel modulators to alter STa
action adds to the available in vivo evidence against the
enterocyte secretory model of diarrhoeal disease.
2.Methods
2.1. In Vivo Perfusion Procedures. All experiments complied
with current UK legislation and were approved after internal
ethical review. Fluid absorption from perfused in vivo rat
jejunal loops was measured by a recirculation procedure
[8] described in detail elsewhere [9]. Adult Sprague-Dawley
female rats, anaesthetised with sodium pentobarbitone
(70mg/kg body weight i.p.) were tracheotomised to allow
unimpeded breathing ofroom air. Anaesthesia was sustained
by periodic i.p.d o s a g es u ﬃcient to maintain abolition of
the hind limb ﬂexor withdrawal reﬂex. Body temperature
was kept at 37◦C by a heating table controlled by rectal
thermistor. Twenty ﬁve cm jejunal loops, starting ten cms
belowtheligament ofTreitz,were perfused viaPVC tubingat
1.8mL/min by peristaltic pump (Crouzet 82344, UK) from a
reservoir containing an initial volume of 25mLs of perfusate
maintained at 37◦C. After three hours, the experiment
was ended by pumping air into the loop and collecting
all remaining perfusate in the reservoir. In addition, the
loop was excised, and any ﬂuid remaining in the loop was
expelled by air with a 20-mL syringe into the reservoir under
gravity drainage. Final recovered volume in the reservoir was
measured to the nearest 0.1mL. Loop length was measured
by ruler after gently laying out the excised loop on the bench
without stretching it. Fluid absorption as measured by this
ﬂuid recovery [10] method is the diﬀerence between the
initial added and ﬁnal recovered volumes after emptying
the perfusate reservoir. It is presented here as microlitres
o fﬂ u i dp e rc ml e n g t ho fi n t e s t i n ep e rh o u rw i t hp o s i t i v e
values meaning absorption. Excised loops were weighed and
also dried to constant weight in an oven at 100◦C, enabling
ﬂuiduptakealso to bestandardised permilligram wet weight
and per gram dry weight. After experiment, the animal was
euthanised. The perfusate was 100mM sodium bicarbonate
solution and 54mM sodium chloride solution to maintain
isotonicity, with 80ng/mL STa as required. Absorption per
gram wet and per dry weight was calculated but are not
presented, as change in standardisation did not alter any
outcome.
2.2. Mean Arterial Blood Pressure Measurements. In prelimi-
naryexperimentstoconﬁrmtheactivityofthepotassiumion
channel agents, arterial blood pressure was measured via a
carotidcannula(Portex,“pink”o.d.0.9mm)usingaStatham
23B pressure transducer coupled via a 1401CED ac/dc
board to a Dell Pentium and recorded by the “Chart” data
capture programme (freeware from J Dempster, University
of Strathclyde, Scotland, UK). Where these drugs were given
as part of the perfusion protocol for assessing their eﬀect
on absorption, blood pressure was measured with a Harvard
pressure transducer, coupled to a Toshiba lap-top computer
andrecordedusingSpike2fordatacaptureviatheCED1401
interface (Cambridge Instruments, Cambs, UK). Heart rate
and respiration frequency (from the Traube-Hering waves)
were also measured from the blood pressure record.
2.3. Administration of Potassium Channel Active Agents.
Cromakalim and clotrimazole were dispensed from stock
solutions of 5mM in ethanol. Experiments were done using
ethanol vehicle to conﬁrm that this was without eﬀect on
the reduced ﬂuid absorption caused by STa. Glibenclamide
was dispensed from a 300mM stock solution in DMSO
(dimethyl sulphoxide). Similar control experiments with
DMSO conﬁrmed that vehicle alone had no eﬀect on STa
action.
Cromakalim and glibenclamide had been previously
identiﬁed as being antisecretory [6], using a procedure with
the relatively short perfusion time of forty-ﬁve minutes.
These substances were investigated in recirculated loops for
a longer time to examine any sustained ability to inhibit
STa action. Because of the longer experimental duration,
these drugs could not be administered exactly as in the
Schirgi-Degen protocol,since cromakalimwas infused intra-
venously at a rate of 63.5ug/kg/min for 45 minutes only,
whereas longer infusion at that rate eventually causes fatal
hypotension. Cromakalim and clotrimazole were, therefore,
administered for the ﬁrst 45 minutes as per the Schirgi-
Degen protocol. This continued until mean arterial blood
pressure fell by 30% below the initial preinfusion value, at
which point dosing stopped and was resumed only when
mean arterial blood pressure again exceeded this value.
Consistency was, therefore, achieved by maintaining a rela-
tively constant extent of depressor activity. The accumulated
dosage rates of 2.85±0.30 (5)mg/kg/hr for clotrimazole and
2.72 ± 0.32 (5)mg/kg/hr for cromakalim were in fact very
close to the Schirgi-Degen protocol rate for cromakalim. As
glibenclamidehas a moderatepressor eﬀect[11],itwasgiven
byperiodici.v.injectionata rateof 7.0mg/kg/hr,closetothe
9.6mg/kg/hr rate given intra-arterially in the Schirgi-Degen
protocol.
2.4. In Vitro Ileum Motility Assay. The ability of the potas-
sium channel active agents to alter intestinal smooth muscle
function was also tested in separate in vitro experimentsJournal of Tropical Medicine 3
by measuring changes in longitudinal tension in the rabbit
ileum mounted in a Burn-Dale apparatus and maintained
in aerated Krebs-Ringer at 37◦C. Tension was measured
by a Harvard instruments tension transducer via an ac/dc
converter board recorded by a Dell Pentium PC using
the “Chart” data capture programme. Rabbit ileal tissue
became available during the time of this study but was not
purposefully selected as a test assay for motility changes.
2.5.Sourceof Chemicals. E.coliSTaandotherchemicalswere
purchasedfromSigmaChemicalCo(Poole,Dorset,UK).For
some of the later experiments, STa from a P16 strain was
used at an equivalentdoseafter the synthetic peptidebecame
unavailable.Therewerenosigniﬁcantdiﬀerencesintheeﬀect
ofSTaonﬂuidabsorption,sincethereducedﬂuidabsorption
of 23.5 ± 8.5( 8 )µL/cm/hr after P16 STa exposure did not
diﬀer signiﬁcantly from the rate of 33.2 ± 8.6( 9 )µL/cm/hr
after Sigma STa exposure. Sagatal (sodium pentobarbitone)
was obtained from Rhone Merieux Ltd (Harrow, London,
UK).
2.6. Statistical Analysis of Data. Results are given as the mean
and standard error of the mean, followed by the number of
experiments, equal to the number of animals, in parenthesis.
Implementation of all statistical analysis was done using
BMDP [12]. Where required, comparison of means was




3.1. Preliminary Experiments. The potassium channel active
agents used to attempt to prevent the eﬀect of STa on ﬂuid
absorption were tested for their known pressor eﬀects on
mean arterial blood pressure in vivo and on smooth muscle
tension in vitro. This was intended to conﬁrm, by using
the same stock solutions, that the drugs introduced into
the small intestine had demonstrable eﬀects on other organ
systems. In a representative group of untreated animals,
systolic/diastolic pressure was 128.3 ± 11.7 (6) over 112.0 ±
13.8 (6)mmHg, giving a mean arterial blood pressure of
117.4±13.6(6)mmHg.Intravenous glibenclamide(Table1)
as a bolus dose of 1.5mg/kg signiﬁcantly (P<. 01) increased
systolic by 21.7 ± 5.8 (7), diastolic by 20.3 ± 4.7( 7 )a n d
mean arterial blood pressure by 20.8 ± 4.8( 7 ) m m H g .
Clotrimazole as a bolus dose of 1mg/kg depressed mean
systolic pressure signiﬁcantly (P<. 01) to 87.2 ± 7.6
(6)mmHg, the diastolic pressure to 66.3 ± 5.6( 6 )m mH g
and mean arterial blood pressure to 73.3 ± 13.1( 6 )m mH g .
Clotrimazole administration caused marked bradycardia in
some animals for 20 seconds or longer, coupled with a
compensatory increase in pulse pressure, as predicted by
the Frank-Starling law of the heart. Cromakalim at a dose
of 24ug/kg depressed mean arterial blood pressure to 58 ±
5 (3) which was signiﬁcantly less (P<. 02) by 38 ± 5
(3)mmHg pressure than control values. A higher dose of
60ug/kgdepressedmean arterial bloodpressure evenfurther
to 42±10 (3)mmHg. In contrast to clotrimazole, there were
no episodes of bradycardia with cromakalim or late pressor
eﬀects as with glibenclamide.However, it was evidentthat all
t h r e ed r u g sp r e p a r e df r o mt h es a m es t o c ks o l u t i o n su s e dt o
perfuse the small intestine showed demonstrable eﬀects on
the cardiovascular system.
The ability of these compounds to aﬀect smooth muscle
tensionwas alsodeterminedinvitro inexperimentsonrabbit
ileum incubated in Krebs-Ringer solution. Conﬁrming the
eﬀects on vascular smooth muscle tone in vivo,7 u M
cromakalim and 100uM clotrimazole reduced intestinal
smooth muscle longitudinal tension (Table 2). Basal tension
infourpreparationswas2.5±0.9(4)gramsrisingtoapeakof
5.9±0.8 (4) grams, giving an average tension of 3.7±0.5( 4 )
grams, a tension amplitude of 3.4 ± 0.9 grams, with a mean
rate of contraction of 13.9 ± 1.1 contractions per minute.
Clotrimazole had no eﬀect on the basal tension but reduced
peak tension signiﬁcantly (P<. 001) to 4.6 ± 0.6( 4 )g r a m s
and reduced average tension and tension amplitude, without
aﬀecting the rate of contraction. Cromokalim similarly
reduced (P<. 05) tension amplitude from 5.1 ± 1.3( 3 )t o
2.8±1.3(3)grams withoutalteringfrequencyofcontraction.
In contrast, 50uM glibenclamide signiﬁcantly (P<. 001)
increased the basal tension from 2.0±0.5( 3 )t o3 .1±0.6( 3 )
grams and also had no eﬀect on frequency of contraction.
These results are not novel and served only to conﬁrm the
blood pressure results in that clotrimazole and cromakalim
reduced smooth muscle tone and glibenclamide showed a
pressor action, as is well known and as others have found
[11, 14, 15].
In a group of animals perfused luminally with STa,
mean arterial blood pressure was 108 ± 11.7( 3 ) m m H g
at the onset of perfusion. After three hours perfusion, the
mean arterial blood pressure in the STa perfused animals
rose to 125 ± 5 (3)mmHg, indicating that pressure was
maintained and unaﬀected by intraluminal STa perfusion.
In a similarly representative group perfused with STa, heart
rate was 375 ± 10 (5) beats per minute, and the respiratory
rate was 53 ± 5 (5) breaths per minute, with neither variable
signiﬁcantly changing over the perfusion period. Hence,
three or more hours of perfusion under anaesthesia did not
lead to respiratory or cardiovascular depression even when
the lumen was perfused with E. coli STa.
3.2. Eﬀect of Luminal and I.v. Glibenclamide on Luminal
Fluid Absorption from the Proximal Jejunum after E. coli
STa Enterotoxin Challenge. When perfused without STa, the
unchallenged jejunum (Figure 1) absorbed ﬂuid at a rate
of 98.8 ± 6.2 (14)µL/cm/hr. In the STa challenged loop,
there was a signiﬁcantly lesser (P<. 001) rate of 28.6 ± 5.8
(17)µL/cm/hr absorption that was also signiﬁcantly higher
(P<. 001) than zero net absorption. When glibenclamide
was added to E. coli STa perfused loops at a concentration
of 100uM, known to normalise the increased membrane
currents found in Caco2 cells after STa exposure [16],
ﬂuid absorption was 24.8 ± 8.9 (6)µL/cm/hr which did
not diﬀer from absorption in the presence of STa without
glibenclamide. This value of ﬂuid absorption was still highly
signiﬁcantly (P<. 001) below control rates of absorption,4 Journal of Tropical Medicine
Table 1: The pressor and depressor eﬀects of clotrimazole (1mg/kg i.v.), glibenclamide (1.5mg/kg i.v.), and cromakalim (8–24ug/kg i.v.)
on the systolic, diastolic, pulse, and mean arterial blood pressure in the anaesthetised rat. Blood pressures are expressed as mmHg tension.
Results are expressed as means ± standard error of the mean with the number of observations in parenthesis or as diﬀerences in the means
before and after intravenous drug administration. Statistical signiﬁcance (aP<. 001; bP<. 02; cP<. 05) for comparison of parameters prior









Control 128 ±12 (6) 112 ± 14 (6) 26 ±3 (6) 117 ±14 (6)
1mg/kgclotrimazole 87±8( 6 ) b 66 ± 6( 6 ) a 27 ±6 (4) 73 ±13 (6)a
Control 116 ±12 (6) 93 ± 14 (6) 23 ±2 (6) 101 ±13 (6)
8ug/kg cromakalim 116 ±9 (3) 94 ± 11 (3) 22 ±2 (3) 101 ±10 (3)
16ug/kg cromakalim 98 ±8 (3) 71 ±9( 3 ) c 27 ±3 (3) 80 ± 9( 3 ) c
24ug/kg cromakalim 76 ±9( 3 ) a 49 ± 3( 3 ) a 27 ±6 (3) 58 ±5( 3 ) a
Control 103 ±6 (7) 77 ± 7 (7) 26 ±4 (7) 86 ±6( 7 )
1.5mg/kg glibenclamide 126 ±10 (7)c 99 ± 10 (7) 26 ±4 (7) 109 ±10 (7)
Table 2: The eﬀect of 100uM clotrimazole, 50uM glibenclamide, and 7uM cromakalim on the tension and rate of smooth muscle
contraction expressed as grams tension in the in vitro rabbit ileum incubated in Krebs-Ringer solution. Results are expressed as means
± standard error of the mean with the number of observations in parenthesis. Statistical signiﬁcance (aP<. 001; bP<. 02; cP<. 05) for











Pre clotrimazole 2.51 ±0.88 (4) 5.90 ±0.76 (4) 3.74 ±0.53 (6) 3.39 ± 0.88 (4) 13.9 ±1.1( 4 )
Post clotrimazole 2.50 ±0.84 (4) 4.63 ±0.55 (4)a 2.61 ±0.72 (6)c 2.18 ±0.81 (4)a 13.4 ±1.5( 4 )
Pre glibenclamide 1.98 ±0.54 (3) 6.69 ±0.79 (3) 4.34 ±0.41 (3) 4.70 ± 1.07 (3) 14.6 ±2.4( 3 )
Post glibenclamide 3.14 ±0.57 (3)a 8.01 ±2.45 (3) 5.58 ±1.51 (3) 4.87 ± 1.90 (3) 13.8 ±2.6( 3 )
Pre cromakalim 1.73 ±0.62 (3) 6.50 ±0.81 (3) 4.12 ±0.26 (3) 5.10 ± 1.33 (3) 14.5 ±1.8( 3 )
Post cromakalim 1.60 ±0.64 (3) 4.37 ±1.62 (3) 2.98 ±1.06 (3) 2.77 ±1.25 (3)c 13.8 ±2.1( 3 )
indicating that simultaneous glibenclamide perfusion had
not improved the poor ﬂuid absorption rates caused by STa
enterotoxin. Glibenclamide at a concentration of 300uM,
known to reduce the short-circuit current increases in tra-
cheal ﬁbroblasts [17], also failed to restore ﬂuid absorption,
since this was 7.4±3.2( 6 )µL/cm/hr, which was signiﬁcantly
(P<. 05) below the rate in the presence of STa but without
glibenclamide.
When glibenclamide was given intravenously (Figure 2),
the mean ﬂuid absorption rate with STa included in the
perfusate was 24.4 ± 11.4( 6 )µL/cm/hr, not signiﬁcantly dif-
ferent from the value of 28.6±5.8(17)µL/cm/hr for luminal
perfusion with STa without glibenclamide. Glibenclamide
perfusion caused a noticeablepressor eﬀectof approximately
16.7 ± 5.1 (5)mmHg which indicated that while there was
no eﬀect on ﬂuid uptake, the familiar eﬀect of glibenclamide
on mean arterial blood pressure was found.
3.3. Eﬀect of Luminal and I.V. Clotrimazole on Luminal
Fluid Absorption from the Proximal Jejunum after E. coli STa
Enterotoxin Challenge. With a 30uM concentration (known
to inhibit completely the increment in short-circuit current
after STa exposure in vitro) of clotrimazole in the lumen as
well as STa, ﬂuid absorption was 11.4 ± 7.0( 4 ) µL/cm/hr,
indicating that ﬂuid absorption hindered by STa was not
improvedbyinclusionofthepotassiumchannel blocker.The
i.v. perfusion of clotrimazole (Figure 2) during STa luminal
perfusion wasalsowithouteﬀectonﬂuidabsorption.During
clotrimazole perfusion, mean ﬂuid absorption was 30.7 ±
4.0( 6 ) µL/cm/hr during STa challenge, and this did not
diﬀer from the value of 28.6 ± 5.8 (17)µL/cm/hr for ﬂuid
absorption in the presence of STa without simultaneous
perfusion i.v.with clotrimazole. Clotrimazole was conﬁrmed
to have the anticipated depressor action on mean arterial
blood pressure.
3.4. Eﬀect of Luminal and I.v. Cromakalim on Luminal
Fluid Absorption from the Proximal Jejunum after E.coli
STa Enterotoxin Challenge. In the presence of 1uM luminal
cromokalim (Figure 1), STa reduced ﬂuid absorption signif-
icantly (P<. 01) to 24.7 ± 8.0 (10)µL/cm/hr, which did not
diﬀer from the value for ﬂuid absorption after STa challenge
alone of 28.6 ± 5.8 (17)µL/cm/hr. When cromakalim was
administered intravenously (Figure 2),during STa perfusion,
net ﬂuid absorption signiﬁcantly worsened to 10.3 ± 6.8
(5)µL/cm/hr, indicatingthatﬂuidabsorptionafterSTaexpo-
sure was not restored to normal values but was worsened by




















Glib + STa + Clotr + Crmk
P <. 001
Figure1:Theeﬀectoncontroljejunalﬂuiduptake(n = 14) invivo
of luminal perfusion with 80ng/mL E. coli STa alone (n = 17) and
also STa in the presence of 300uM (n = 6) luminal glibenclamide,
30uM luminalclotrimazole(n = 4),and1uM luminalcromakalim
(n = 10). Results are presented as the mean and standard error
of the mean. Perfusion with STa caused a signiﬁcant (P<. 001)
reduction in ﬂuid uptake that was unaﬀected by the luminal




















Glib + STa + Clotr + Crmk
P <. 001
Figure 2: The eﬀect of intravenous perfusion by jugular vein
of glibenclamide (n = 6) at 7.0mg/kg/hr, clotrimazole (n = 5)
at 2.85mg/kg/hr, and cromakalim (n = 5) at 2.72mg/kg/hr on
net ﬂuid absorption from the proximal jejunum of the rat in
vivo perfused luminally with 80ng/mL E. coli STa heat stable
enterotoxin. For comparison, ﬂuid absorption without perfusion
with STa (n = 14) and with perfusion with STa (n = 17) are
given. Fluid absorption in the presence of STa was signiﬁcantly
lower (P<. 001) than control values. I.v. perfusion of the indicated
potassium channel active agents in the presence of STa was not
signiﬁcantlydiﬀerent from STa perfusion alone.
4.Discussion
A prevalent theory regarding secretion by the small intestine
during diarrhoeal disease proposes that the enterocytes
secrete chlorideion into the lumen.This isa necessary aspect
of any hypothesis concerning an enterocyte origin for ﬂuid
secretion, because water movement occurs normally only
in response to osmotic gradients. The mucosally secreted
chloride and associated sodium ions purportedly increase
osmolarity at the mucosal surface, causing ﬂuid ﬂow into the
small intestinal lumen. To achieve chloride secretion from
the enterocyte interior against the disadvantageous chemical
gradient, this model incorporates enhanced potassium ion
permeability to maintain a favourable electrical gradient.
According to the enterocyte secretion concept, potassium
ion exits across the basolateral membrane and maintains
the mucosal membrane potential diﬀerence. As sustained
secretion requires increased basolateral potassium ion per-
meability, ﬂuid secretion should be inhibited by potassium
channel blockers and possibly should also be accelerated by
potassium channel openers.
Evidence for this particular aspect of the enterocyte
secretion model derives largely from in vitro short-circuit
current and ion eﬄux studies in tumour cells in Ussing
chambers although neither parameter measures secretion
as the mass transport of ﬂuid. Prostaglandin E1 or E. coli
STa increases a barium inhibitable rubidium ﬂux across
the serosal membrane, increases short circuit currents, and
alters sodium and chloride ﬂuxes across T84 cells [18,
19]. Potassium channel inhibitors such as glibenclamide
are also CFTR inhibitors in tracheal ﬁbroblasts [17]a n d
should inhibit secretion. In addition, the potassium channel
inhibitor clotrimazole inhibits elevated short-circuit current
after forskolin treatment in T84 cells [5]. Clotrimazole does
not aﬀect mucosal membrane chloride conductance [4],
and hence, its ability to prevent cholera toxin secretion is
also attributed to altered potassium ion conductance. In
addition, clotrimazole reduces the increased short-circuit
current caused by cholera and E. coli STa enterotoxin [3].
Hence, in vitro evidence from electrical events and ion eﬄux
studies points to potassium channel blockers preventing
secretion.
In contrast, in vivo pharmacological tests of the role
of enhanced enterocyte potassium ion permeability during
enterotoxin challenge are rare, and the results are contradic-
tory. Since clotrimazole [4] and glibenclamide [16] reduce
the short-circuit current increase after STa challenge, these
drugs should inhibit the action of this supposedly secretory
enterotoxin. When tested in vivo by measuring loop weight,
STa was modestly secretory, as was glibenclamide alone
without toxin [6]. In contrast, cromakalim improved both
normal absorption and also E. coli STa-mediated secretion
despitebeingapotassiumchannelopenerthatshouldworsen
or at least not improve secretion. Hence, neither agent
aﬀected ﬂuid movement in the STa challenged jejunum
in a manner predicted by the potassium ion permeability
concept. The ability of cromakalim, the potassium channel
opener,topreventSTaactionandtheabilityofglibenclamide
to cause secretion despite being a potassium channel blocker
do not accord with the enterocyte potassium permeability
model at all.
In the present experiments, neither luminal nor intra-
venous administration of clotrimazole, glibenclamide, or
cromakalim aﬀected the reduced ﬂuid absorption occurring
after exposure to E. coli STa enterotoxin. STa reduces ﬂuid6 Journal of Tropical Medicine
absorption severely, but if the potassium ion permeability
model is valid, clotrimazole and glibenclamide should
improve the poor ﬂuid absorption, and cromakalim should
perhaps worsen it. Although the theory predicts this, the
observations of Shirgi-Degen and Beubler are at variance
bothwiththepresentobservationsandwithsecretiontheory.
A three-hour perfusion time as used here allows large
changes in volume to arise, since a reduction of 60µL/cm/hr
in the rate of ﬂuid absorption after STa challenge in a 25cm
loop translates into 4.5 millitres of ﬂuid additionally present
in the ﬂuid reservoir at the end of experiment. Any net
secretion and also any ability to inhibit secretion will be
detected in this comparatively robust system and, in fact,
was not found. Over a three-hour perfusion experiment,
mean arterial blood pressure rose from 100mmHg to
120mmHg at the end of the experiment, indicating that
mean arterial blood pressure is not compromised. Using
therecoveredvolumetechnique,glibenclamide,cromakalim,
and clotrimazole were shown not to have any ameliorating
eﬀect on STa induced reductions in ﬂuid absorption.
To establish that the potassium channel modulators
were active prior to intravenous administration or luminal
perfusion, aliquots from the stock solutions were tested
in separate, unrelated experiments. Intravenous injections
of cromakalim and clotrimazole reduced mean arterial
blood pressure in vivo in the rat, and glibenclamide had
a moderate pressor eﬀect, as others have found [11, 20].
These agents when given intravenously are unlikely not to
have reached the enterocytes, since the diﬀusion path length
from capillary to enterocyte is less than ﬁve micrometers.
Intestinal capillaries, unlike normal capillaries, are known
to have fenestrations that face the villi, and there are no
substantial barriers to permeation. It is also unlikely that
luminalperfusion didnotachievedeliverytotheenterocytes,
sincethese drugs are lipidsolublewith dissociation constants
that allow absorption. It might be argued that secretion
of ﬂuid may keep luminally administered drug oﬀ the
surface, but given the diﬀusion coeﬃcients of molecules of
this size, the required adverse convection currents can be
calculated to be orders of magnitude above hypothesised
ratesofsecretion.Inaddition,theconcentrationsofdimethyl
sulphoxide and ethanol are known to have no eﬀect on
STa-mediated guanylate cyclase activation [21]. Conﬁrming
this, luminal STa reduced ﬂuid absorption in all experiments
regardless of presence of vehicle. Where vehicle alone was
perfused as a control experiment, no eﬀect on STa action
was noted. The lack of eﬀect of potassium ion channel active
compounds is not because of interference from dispersant
vehicle and highly unlikely to be because of inability to reach
the enterocyte.
The cardiovascular actions of the selected agents may
explain diﬀerences between this study and that of Shirgi-
Degen and Beubler [6]. Luminal volume as measured by
the ﬂuid recovery can only reﬂect secretion or absorption
across the luminal membrane. In contrast, any method
based on loop weight also measures additionally ﬂuid
entering and leaving the vasculature, causing changes in
the interstitial volume. Since measurement of loop weight
also includes interstitial volume, which the luminal ﬂuid
recovery method does not, diﬀering ﬁndings might result
from vasomotor changes. This might explain why potassium
channel active agents do not alter ﬂuid absorption after
STa challenge when assessed by luminal volume recovery in
the present experiments but seem to reduce secretion when
this is deﬁned and measured as an increase in loop weight.
This could also explain why cromakalim is antagonized by
glibenclamide in the Beubler study, as a depressor and a
pressor substance compete to alter peripheral resistance and
hence intestinal interstitial volume. If these changes are not
explicablebylocalvascular changes within theintestine, then
any explanation defaults to the level of the enterocyte.
Sincethese compounds donotinhibit ﬂuid movementin
theSTachallengedintestinewhentherecoveredvolumetech-
nique is used, then the potassium channel activation model
does not apply despite the availability of in vitro evidence
indicating that it should be relevant. One explanation for
the in vitro r e s u l t si st h a tr u b i d i u me ﬄux and short-circuit-
current changes relate to the sodium: potassium pump
rate and not to chloride secretion. The known inhibition
by clotrimazole of the sodium pump may explain the fall
in short circuit current in isolated cells [22]. Similarly,
enhanced potassium loss from the cells may arise from
the sodium pump working at a faster rate to re-establish
normal rates of ﬂuid absorption when the cell is challenged
by bacterial enterotoxin. This could explain the undoubted
eﬀects of potassium channel active agents on electrical
current without any real eﬀect on ﬂuid movement.
In conclusion, potassium ion active agents do not restore
in vivo the reduced net ﬂuid movement caused by E. coli STa
enterotoxin, widely regarded as causing secretion. Enhanced
potassium ion permeability to maintain the electrical gra-
dient for adequate luminal exit of chloride ion is a sub-
hypothesis of the chloride secretory model [23] rather than a
necessary corollary. Falsiﬁcation of this concept alone does
not itself falsify the chloride secretion hypothesis for ﬂuid
movement into the intestine. However, the action of E.
coli STa enterotoxin is not prevented by potassium channel
modulators despite promising data from in vitro techniques
that are assumed to but may not measure secretion. The lack
ofeﬀectofpotassiumchannelmodulatorsisfurtherevidence
that STa is not a secretory toxin but acts solely by inhibiting
sodium ion and ﬂuid absorption.
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